

References

This is the reference list to the ACE Clinical Guidance "Oral anticoagulation for atrial fibrillation".

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991;22(8):983-988.
2. Yap KB, Ng TP, Ong HY. Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore: a population-based study. *J Electrocardiol*. 2008;41(2):94-98.
3. National Registry of Diseases Office. Singapore Stroke Registry Annual Report 2020. Available from: <https://nrdo.gov.sg/publications/stroke> [Accessed 24 May 2023].
4. Xue Z, Zhang H. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation. *Stroke*. 2019;50(10):2819-2828.
5. Tse H, Teo WS, Siu CW, et al. Prognosis and treatment of atrial fibrillation in Asian cities: 1-year review of the Asia-Pacific Heart Rhythm Society Atrial Fibrillation Registry. *Europace*. 2022;euab327.
6. Chan YH, Chao TF, Chen SW, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. *Heart Rhythm*. 2020;17(12):2102-2110.
7. Lee KN, Choi JI, Boo KY, et al. Effectiveness and Safety of Off-label Dosing of Non-vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients. *Sci Rep*. 2020;10(1):1801.
8. Lee SR, Choi EK, Park SH, et al. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. *Eur Heart J Cardiovasc Pharmacother*. 2021;7(5):415-423.
9. Xu, W, Lv M, Wu T, et al. Off-label dose direct oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation: A new evidence of Asian dose. *Int J Cardiol*. 2023;371:184-190.
10. Cho MS, Yun JE, Park JJ, et al. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing. *Am J Cardiol*. 2020;125(9):1332-1338.
11. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet*. 2007;370(9586):493-503.
12. Wu VCC, Wu M, Aboyans V, et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. *Heart*. 2020;106(7):534.
13. Nielsen PB, Overvad TF. Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA₂DS₂-VASc versus CHA₂DS₂-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution. *Thromb Haemost*. 2020;120(06):894-898.
14. Okumura K, Inoue H, Atarashi H, et al. Validation of CHA₂DS₂-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. *Circ J*. 2014;78(7):1593-1599.
15. Chao TF, Lip GYH, Lin YJ, et al. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities. *Eur Heart J*. 2019;40(19):1504-1514.
16. Choi SY, Kim MH, Kim HB, et al. Validation of the CHA₂DS₂-VA Score (Excluding Female Sex) in Nonvalvular Atrial Fibrillation Patients: A Nationwide Population-Based Study. *J Clin Med*. 2022;11(7).
17. National Institute for Health and Care Excellence (NICE). Atrial fibrillation: diagnosis and management. London: National Institute for Health and Care Excellence (UK); 2021.
18. Chao TF, Joung B, Takahashi Y, et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. *Thromb Haemost*. 2022;122(1):20-47.
19. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. *Chest*. 2018;154(5):1121-1201.

20. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42(5):373-498.
21. Barnes GD, Ageno W, Ansell J, et al. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. *J Thromb Haemost*. 2015;13(6):1154-1156.
22. Carnicelli AP, Hong H, Connolly SJ, et al. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. *Circulation*. 2022;145(4):242-255.
23. Wang KL, Lip GYH, Lin SJ, et al. Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation. *Stroke*. 2015;46(9):2555-2561.
24. Agency for Care Effectiveness (ACE). Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation. Technology Guidance. 2022. Available from: [https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/details/novel-oral-anticoagulants-\(noacs\)-for-the-prevention-of-stroke-and-systemic-embolism-in-non-valvular-atrial-fibrillation](https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidances/details/novel-oral-anticoagulants-(noacs)-for-the-prevention-of-stroke-and-systemic-embolism-in-non-valvular-atrial-fibrillation) [Accessed 24 May 2023]
25. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. *N Engl J Med*. 2013;369(13):1206-1214.
26. Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation. *N Engl J Med*. 2022;387(11):978-988.
27. Li D, Chang P, Zhang H, et al. The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis. *Eur J Clin Pharmacol*. 2023.
28. Cao Y, Zheng Y, Li S, et al. An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve. *Front Cardiovasc Med*. 2022;9:899906.
29. Guimarães HP, Lopes RD, de Barros e Silva PGM, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. *N Engl J Med*. 2020;383(22):2117-2126.
30. Pan, KL, Singer DE, Ovbiagele B, et al. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. *Am Heart J*. 2017;6(7):e005835.
31. Martha JW, Pranata R, Raffaello WM, et al. Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis. *Front Cardiovasc Med*. 2021;8:764356.
32. Wong WH, Yip CY, Sum CL, et al. A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore. *Ann Acad Med Singap*. 2016;45(3):98-105.
33. Joosten LPT, van Doorn S, van de Ven PM, et al. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. *Circulation*. 2023;0(0).
34. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. *Circulation*. 1994;89(2):635-641.
35. Al Rawahi MN, Al-Maqbali JS, Al Noumani J, et al. Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Moderate to Severe Mitral Stenosis: A Systematic Review. *Cureus*. 2023;15(1):e33222.
36. Wang X, Wang T, Chen X, et al. Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses. *J Am Med Dir Assoc*. 2023;24(8):1233-9.e26.
37. Benz AP, Johansson I, Dewilde WJM, et al. Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. *Eur Heart J Cardiovasc Pharmacother*. 2022;8(7):648-659.
38. Manaktala R, Kluger J. Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation. *J Osteopath Med*. 2017;117(12):761-771.

39. Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. *Can J Cardiol.* 2020;36(12):1847-1948.
40. van Es N, De Caterina R, Weitz JI. Reversal agents for current and forthcoming direct oral anticoagulants. *Eur Heart J.* 2023;44(20):1795-1806.
41. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. *EP Eur.* 2021;23(10):1612-1676.
42. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med.* 2011;365(11):981-992.
43. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med.* 2011;365(10):883-891.
44. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med.* 2009;361(12):1139-1151.
45. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med.* 2013;369(22):2093-2104.
46. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. *Circulation.* 2019;140(2):e125-e51.
47. Ministry of Health Singapore. MOH Clinical Pharmacy Practice Guidelines: Anticoagulation - Warfarin. 2006. Available from: https://www.google.com/search?q=MOH+Clinical+Pharmacy+Practice+Guidelines+warfarin&og=MOH+Clinical+Pharmacy+Practice+Guidelines+warfarin&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBCdMxNTJqMGo0qAlAsAIA&sourceid=chrome&ie=UTF-8 [Accessed 28 April 2023]
48. Wigle P, Hein B, Bloomfield HE, et al. Updated guidelines on outpatient anticoagulation. *Am Fam Physician.* 2013;87(8):556-566.
49. Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. *Blood.* 2019;133(5):425-435.
50. Ng HJ, Chee YL, Ponnudurai K, et al. Consensus recommendations for preventing and managing bleeding complications associated with novel oral anticoagulants in Singapore. *Ann Acad Med Singap.* 2013;42(11):593-602.
51. Liu X, Wang S, He W, et al. HAS-BLED vs. ORBIT scores in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis. *Front Cardiovasc Med.* 2023;9:1042763.
52. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest.* 2010;138(5):1093-1100.
53. Chao TF, Liao JN, Tuan TC, et al. Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients. *Thromb Haemost.* 2019;119(07):1162-1170.
54. Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. *J Thromb Thrombolysis.* 2016;41(1):206-32.
55. Tran H, Joseph J, Young L, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. *Australasian Society of Thrombosis and Haemostasis. Intern Med J.* 2014;44(6):525-36.